Skip to Main Content

Paper Details

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Br J Dermatol
8
2021
CDKN2A, CDKN2A (cyclin dependent kinase inhibitor 2A) region, CTNND1, EGFR, EPC, EPC patient-derived cell line, Eccrine porocarcinoma, MAP2K1, MAPK, MEK, MEK1, PAK1, RAC1, TP53, activated kinase 1], cancer, catenin delta 1, cyclin dependent kinase inhibitor 2A, epidermal growth factor receptor, mEPC, metastatic EPC, metastatic porocarcinoma, mitogen-activated protein kinase kinase 1, p21, patient, patient-derived cell line, skin cancer, tumour, tumour protein 53
Author NameAffiliation
Peter Horak
Peter HorakNational Center for Tumor Diseases (NCT) Heidelberg and DKFZ
Barbara Hutter
Barbara Hutter
Barbara Hutter
Barbara Hutter
Barbara Hutter
Barbara Hutter
Albrecht Stenzinger
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg
Stefan Fr??hling
Stefan Fr??hlingNational Center for Tumor Diseases (NCT) Heidelberg and DKFZ
  • 1 - 12

Datasets

Release 1.2